Serodus AS Licenses Compound from Roche for the potential treatment of heart failureSerodus AS announced that it has a licensing agreement with Roche registered for a selective serotonin – 4 antagonist for the treatment of heart failure .
Overall, the presence of certain MC1R variants with more than two – fold increased risk of melanoma ,, but this risk largely on the patient, a higher risk usually considered a higher risk to be limited.
Serodus, a Norwegian biopharmaceutical company focused on the development of innovative drugs for cardiovascular disease, RO1160367, a drug candidate has prepared a Phase II proof-of-concept study in heart failure to be licensed .Elderly people supporting live in supportive districts in order to survive a much better chance a stroke as other senior citizens, writing scientists on the University of Minnesota and Rush University to the journal StrokeCollection. Added, however, the authors find that not with a good neighboring appears no effects on your chances of getting stroke stroke.
These authors could no these this among older people among the elderly to African-American neighborhoods. T Clarksville said:.